Reliable Data You Can Trust
Reliable Data You Can Trust
A recent
report published by Infinium Global Research on acetazolamide market provides
in-depth analysis of segments and sub-segments in the global as well as
regional acetazolamide market. The study also highlights the impact of drivers,
restraints, and macro indicators on the global and regional acetazolamide
market over the short term as well as long term. The report is a comprehensive
presentation of trends, forecast and dollar values of global acetazolamide
market. According to the report, the global acetazolamide market is projected
to grow at a CAGR of 4.1% over the forecast period of 2019-2025.
Acetazolamide
is a carbonic anhydrase(CA) inhibitor, works to cause the accumulation of
carbonic acid by preventing its breakdown. It works to absorb chloride,
bicarbonate, and sodium to make blood more acidic. It is used to treat a large
number of the disease such as glaucoma, periodic paralysis, heart failure,
altitude sickness, epilepsy, idiopathic intracranial hypertension, and many
others. It is an important remedy to treat high altitudes related problems such
as AMS (Acute Motion Sickness), HAPE (High Altitude Pulmonary Edema) and HACE (High
Altitude Cerebral Edema). During the treatment of high altitude related
problems, it inhibits the carbonic anhydrase enzymes, which helps to excretion
of bicarbonate in the urine. Aftermath, it hastens the acclimatization and
removes high altitude disorders. Further, acetazolamide is the first generation
CA inhibitors(CAIs) used for the treatment of the glaucoma disease. It is used
as a systematic drug to treat glaucoma. It is used singly or in combination
with other drugs as adrenergic agonist/antagonist, to treat the glaucoma
problem.
The growing
prevalence of glaucoma, periodic paralysis, heart failure, altitude sickness,
epilepsy, idiopathic intracranial hypertension, and other diseases are expected
to boost the demand of the acetazolamide around the world. But, some side
effects owing to excessive application of the acetazolamide such as dizziness,
lightheadedness, frequent urinating during the medication, vomiting are forcing
the consumers to use other alternatives of acetazolamide. However, its growing
availability as generic medicine around the world and no effective alternatives
for several diseases as altitude sickness is expected to boost the growth of
the market in the near future. Additionally, its low price factor owning to its
generic medicine category is helping to grow its market around the world.
Further, growing innovation in the introduction of different type of acetazolamide based product in the potential market is helping to grow the
demand for this medicine. Recently, Zydus Cadila got final approval from USFDA
to market acetazolamide based injection USP, 500 mg per single dose vial in
around the globe. This new product launch is expected to boost the demand for acetazolamide injection among developed and developing countries.
Among the
regions, Asia-Pacific is the largest market of the acetazolamide products,
owing to the availability of several drug manufacturing companies in this
region. Additionally, availability of the large patient pool for several
diseases, and government support to provide basic medicine at the low price is
boosting the demand of the acetazolamide products in this region. The North
America and Europe are following the Asia-Pacific market.
The report on
global acetazolamide market covers segments such as dosage form, disease, and
distribution channel. On the basis of dosage form, the sub-markets include
injection, capsules, and tablets. On the basis of disease, the sub-markets
include glaucoma, epilepsy, altitude sickness, periodic paralysis, idiopathic
intracranial hypertension, heart failure, and other diseases. On the basis of
distribution channel, the sub-markets include hospital, retail drug store, and
online drug store.
The report
provides profiles of the companies in the market such as Emcure Pharmaceuticals
Limited, Mylan N.V., X-Gen Pharmaceuticals, Inc, West-Ward Pharmaceutical
Corp., Strides Pharma Science Limited(Strides), Nostrum Laboratories Inc,
Heritage Pharmaceuticals, Sun Pharmaceutical Industries Limited, Lannett Co
Inc, and Zydus Pharmaceuticals (USA) Inc.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of acetazolamide market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.